Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.

Journal article

BACKGROUND: New vaccines to prevent tuberculosis are urgently needed. MVA85A is a novel viral vector TB vaccine candidate designed to boost BCG-induced immunity when delivered intradermally. To date, intramuscular delivery has not been evaluated. Skin and muscle have distinct anatomical and immunological properties which could impact upon vaccine-mediated cellular immunity. METHODS: We conducted a randomised phase I trial comparing the safety and immunogenicity of 1×10(8)pfu MVA85A delivered ...

Expand abstract

Authors: Meyer, J; Harris, SA; Satti, I; Poulton, I; Poyntz, H

• Publication status: Published
• Journal: Vaccine
• Volume: 31
• Issue: 7
• Pages: 1026-1033
• Publication date: 2013-02-01
• DOI: 10.1016/j.vaccine.2012.12.042
• EISSN: 1873-2518
• ISSN: 0264-410X
• Language: English
• Keywords: Adolescent; Receptors, Chemokine; Humans; Interferon-gamma; Injections, Intramuscular; Adult; Middle Aged; Viral Vaccines; Tuberculosis Vaccines; Female; Gene Expression; Male; Drug-Related Side Effects and Adverse Reactions; Injections, Intradermal; T-Lymphocytes; Young Adult